X

Appropriate Use of Antiepileptic Drugs for Prophylaxis in the Neurosurgical Care Unit

By: Anthony Vecchione, PharmD Candidate c/o 2016 - Seizures are a well-described complication of acute brain injury and neurosurgery. Antiepileptic…

eMAR

A Word from the Immediate Past Editor-in-Chief

By: Tasnima Nabi, Co-Copy Editor [Content-focused] - Dear Readers, When I received Volume 1, Issue 1 of the Rho Chi…

eMAR

2016 Rho Chi Induction

By: Jack (Hongkai) Bao, Staff Editor & Sang Hyo Kim, Section Editor (Puzzles) - In an atmosphere populated with restless…

eMAR

Letter from the President

By: Ajla Dupljak, President-Elect, Rho Chi Beta Delta Chapter - Greetings! My name is Ajla Dupljak and it is with…

eMAR

Imlygic™, the First Oncolytic Viral Therapy in the US

By: Gabrielle Plaia, PharmD Candidate Class of 2016 - On Oct. 27 2015, the Food and Drug Administration announced the…

eMAR

Dabigatran Antidote Provides New Option for Targeted Anticoagulant Reversal

By: Svetlana Akbasheva, Staff Editor - Dabigatran etexilate mesylate (Pradaxa®) is an oral anticoagulant that functions as a direct thrombin…

eMAR

States Expand Access to Naloxone

By: Svetlana Akbasheva, Staff Editor - Naloxone (Narcan®) is a rapid-acting, potentially life-saving drug for acute opioid overdose. An opioid…

eMAR

Novel Anticoagulant Approved For Use in Embolism Prevention

By: Maryam Ahmed and Lyudmila Krivovyaz, Pharm.D Candidates, c/o 2016 - Each year, more than 795,000 Americans suffer from a…

eMAR

Antipsychotic-Induced Obsessive-Compulsive Disorder

By: Cyril Collantes, PharmD Candidate c/o 2016 - Obsessive-Compulsive Disorder (OCD) is characterized by two predominant psychiatric components: obsession and…

eMAR

New Therapeutic Options for IBS-D

By: Benedette Cuffari, B.S. of Toxicology Candidate 2016 - Affecting 10%-15% of the population in Western countries, irritable bowel syndrome…

eMAR